tiprankstipranks
Trending News
More News >
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Advertisement

Oric Pharmaceuticals (ORIC) AI Stock Analysis

Compare
378 Followers

Top Page

ORIC

Oric Pharmaceuticals

(NASDAQ:ORIC)

Rating:43Neutral
Price Target:
Oric Pharmaceuticals' overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company's stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.
Positive Factors
Analyst Recommendation
Analyst recommends a Buy rating, indicating confidence in ORIC Pharmaceuticals' future performance.
Drug Development
ORIC-944 has potentially best-in-class drug properties for the emerging PRC2 inhibitor class for prostate cancer.
Financial Position
The company's strong cash position, with approximately $436.4 million in cash and investments, supports future development plans.
Negative Factors
Clinical Development Risks
Risks include inability to advance ORIC-114 and ORIC-944 in clinical development and delays in moving into pivotal trials.
Financial Challenges
Financial results showed a net loss of $0.47 per share, highlighting ongoing financial challenges.
Safety Concerns
Investors focused on the safety profile with a high treatment-related Grade ≥3 adverse event rate of 49%.

Oric Pharmaceuticals (ORIC) vs. SPDR S&P 500 ETF (SPY)

Oric Pharmaceuticals Business Overview & Revenue Model

Company DescriptionOric Pharmaceuticals (ORIC) is a biopharmaceutical company focused on discovering and developing innovative treatments for cancer. The company operates primarily in the biotechnology sector, leveraging its expertise in oncology to address mechanisms of therapeutic resistance. Its core products are centered around developing small molecule drugs designed to counteract resistance in cancer treatments, thereby improving the efficacy of existing therapies and extending patient survival rates.
How the Company Makes MoneyOric Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its pipeline by advancing its proprietary compounds through clinical trials and obtaining regulatory approval, which then allows it to either market these drugs directly or license them to larger pharmaceutical companies. Key revenue streams include potential milestone payments, royalties from partnerships with larger pharmaceutical companies, and future product sales upon successful drug approval. Oric may also engage in strategic collaborations and partnerships to co-develop or out-license its technologies, which can provide upfront payments and shared development costs, contributing to its revenue.

Oric Pharmaceuticals Financial Statement Overview

Summary
Oric Pharmaceuticals shows typical characteristics of a biotechnology firm in the development stage, with no revenue generation, negative profitability metrics, and reliance on equity and financing to fund operations. While the balance sheet demonstrates financial stability through high equity and cash reserves, the lack of revenue and ongoing cash consumption present significant risks.
Income Statement
10
Very Negative
Oric Pharmaceuticals has consistently reported zero revenue over the years, indicating that the company is still in the development phase typical for biotechnology firms. The persistent net losses and negative EBIT and EBITDA highlight ongoing operational challenges without any revenue to offset costs. This results in minimal profitability and growth metrics.
Balance Sheet
60
Neutral
The company maintains a strong equity position with zero total debt, resulting in a favorable debt-to-equity ratio. The high equity ratio indicates financial stability, while the substantial cash reserves suggest good liquidity to support ongoing operations and development activities. However, the continuous net losses may eventually impact equity if no revenue generation occurs.
Cash Flow
40
Negative
Operating cash flows have been consistently negative, reflecting the company's cash consumption due to ongoing operations without revenue inflows. The company has managed to maintain liquidity through financing activities, as seen in positive financing cash flows. However, free cash flow remains negative, highlighting the need for continual financing to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.07M0.000.000.000.000.00
Gross Profit-349.00K-1.11M-1.03M-966.00K-897.00K-970.00K
EBITDA-149.10M-126.74M-109.75M-88.16M-77.97M-72.73M
Net Income-137.25M-127.85M-100.70M-89.12M-78.72M-73.70M
Balance Sheet
Total Assets346.86M274.14M252.01M247.18M298.64M299.00M
Cash, Cash Equivalents and Short-Term Investments282.51M255.96M208.19M206.27M236.98M293.60M
Total Debt0.009.36M10.21M2.66M1.93M0.00
Total Liabilities22.86M31.02M27.92M24.83M25.67M9.22M
Stockholders Equity324.00M243.12M224.09M222.35M272.98M289.78M
Cash Flow
Free Cash Flow-120.86M-113.85M-86.54M-77.22M-60.48M-45.94M
Operating Cash Flow-120.23M-112.66M-85.69M-75.14M-59.54M-45.27M
Investing Cash Flow11.24M22.14M-43.40M-109.25M158.44M-215.96M
Financing Cash Flow135.01M126.55M85.66M25.23M49.13M250.51M

Oric Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10.88
Price Trends
50DMA
10.40
Positive
100DMA
8.61
Positive
200DMA
8.53
Positive
Market Momentum
MACD
0.14
Negative
RSI
63.03
Neutral
STOCH
84.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 10.88 is above the 20-day moving average (MA) of 9.92, above the 50-day MA of 10.40, and above the 200-day MA of 8.53, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 63.03 is Neutral, neither overbought nor oversold. The STOCH value of 84.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.

Oric Pharmaceuticals Risk Analysis

Oric Pharmaceuticals disclosed 99 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Oric Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
45
Neutral
-60.19%56.60%
44
Neutral
$2.31B-134.54%-25.61%
43
Neutral
$1.05B-43.82%-7.33%
41
Neutral
$385.91M-52.18%187.52%26.32%
34
Underperform
$419.83M-31.16%50.77%
33
Underperform
$770.93M-109.12%7.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ORIC
Oric Pharmaceuticals
10.88
1.09
11.13%
CELC
Celcuity
55.68
40.45
265.59%
CKPT
Checkpoint Therapeutics
4.26
2.13
100.00%
AUTL
Autolus Therapeutics
1.46
-2.63
-64.30%
SANA
Sana Biotechnology
2.96
-2.07
-41.15%
ERAS
Erasca
1.61
-1.46
-47.56%

Oric Pharmaceuticals Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
Positive
Mar 14, 2025

On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment to the 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 1,100,000, totaling 2,250,000 shares. This move, made without stockholder approval under Nasdaq rules, aims to attract new employees and facilitate mergers or acquisitions, aligning with the company’s strategic growth and talent acquisition objectives.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025